Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study
Show others and affiliations
2026 (English)In: Hepatology, ISSN 0270-9139, E-ISSN 1527-3350, Vol. 84, no 1, p. 204-215Article in journal (Refereed) Published
Abstract [en]

Background and Aims:

Advanced histologic fibrosis is a major predictor of mortality in metabolic dysfunction–associated steatotic liver disease (MASLD). We aimed to identify advanced fibrosis clinical determinants across diverse MASLD populations and to assess the prognostic value of noninvasive markers (NITs) of fibrosis for adverse outcomes.

Approach and Results:

The Global MASLD (G-MASLD) enrolled biopsy-confirmed MASLD patients with clinical, histologic, and noninvasive test (NIT) data. Factors associated with the presence of advanced histologic fibrosis (F3-F4) in MASLD and clinical outcomes were assessed. There were 17,792 patients with MASLD. Advanced fibrosis (≥F3) was present in 35%. The prevalence of type 2 diabetes (T2D) increased stepwise with fibrosis stage, from 28% in F0 to 70% in F4 (trend p<0.0001). Independent predictors of advanced fibrosis included older age, T2D, and obesity, although the association with obesity varied by region. Among patients with follow-up (mean 6.6 y), 6.5% died and 10.1% experienced a clinical event. Older age, male sex, T2D, and obesity were independent predictors of both mortality and clinical events (p<0.05). Fibrosis severity, whether defined histologically or by NITs, was strongly associated with higher risks of death and liver-related outcomes (all adjusted HR>1.0, p<0.001). Five-year mortality was 2.1% overall, rising to 8.3% in patients with cirrhosis, and exceeded 10% among those with high-risk NIT score values.

Conclusions:

In this large global biopsy-based MASLD cohort, advanced fibrosis was highly prevalent and strongly linked to T2D. Both histologic fibrosis and NITs were independent predictors of mortality and clinical outcomes, underscoring the prognostic value of fibrosis assessment with NITs.

Place, publisher, year, edition, pages
Wolters Kluwer, 2026. Vol. 84, no 1, p. 204-215
Keywords [en]
biomarkers, chronic liver disease, diagnostic thresholds, metabolic syndrome, noncommunicable diseases, steatohepatitis, outcomes, steatotic liver disease
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:uu:diva-573374DOI: 10.1097/HEP.0000000000001617ISI: 001662823500001Scopus ID: 2-s2.0-105037345205OAI: oai:DiVA.org:uu-573374DiVA, id: diva2:2021226
Available from: 2025-12-12 Created: 2025-12-12 Last updated: 2026-09-28Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textScopus

Authority records

Vessby, Johan

Search in DiVA

By author/editor
Vessby, Johan
By organisation
Gastroenterology/Hepatology
In the same journal
Hepatology
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 47 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf